Tazeen Ahmad
BofA Securities, Research Division

Hello everybody. Welcome back to the Bank of America Healthcare Conference. I'm Tazeen Ahmad. I'm one of the senior biotech analysts here at the bank. Our next presenting company is IDEAYA Biosciences. And sitting up here on stage with me are two members from the management team. We've got Yujiro Hata, who is Chief Executive Officer; and Josh Bleharski, who is, of course, CFO. Gentlemen, thank you for making the trip to see us today.

Joshua Bleharski
Chief Financial Officer

Tazeen, thank you.

Yujiro Hata
Founder, President, CEO & Director

Thanks so much for hosting us. Tazeen, really pleasure to have us. And Josh and I are looking forward to the discussion today. Thank you.

Tazeen Ahmad
BofA Securities, Research Division

Okay. So really quickly, for those who may not be as familiar with the company, can you just give us an overview of IDEAYA sort of the platform, where you are in terms of developing some key data catalysts and we can go from there.

Yujiro Hata
Founder, President, CEO & Director

Sure. So IDEAYA Biosciences, we're a leading precision medicine oncology company. Our lead program is darovasertib. We just recently had top line results in first-line metastatic uveal melanoma. We also recently just received Fast Track designation. So we'll be submitting our first pre-submission for the NDA next week. And so that's all going as planned.

We also have two additional Phase III registrational studies that are ongoing beyond metastatic uveal melanoma, including in a neoadjuvant setting as well